We developed and validated a measurement instrument (CLASI-Cutaneous Lupus Erythematosus Disease Area and Severity Index) for lupus erythematosus that could be used in clinical trials. The instrument has separate scor...We developed and validated a measurement instrument (CLASI-Cutaneous Lupus Erythematosus Disease Area and Severity Index) for lupus erythematosus that could be used in clinical trials. The instrument has separate scores for damage and activity. A group of seven American Dermato-Rheumatologists and the “ American College of Rheumatology Response Criteria Committee on SLE (systemic lupus erythematosus)” assessed content validity. After a preliminary session, we conducted standardized interviews with the raters and made slight changes to the instrument. The final instrument was evaluated by five dermatologists and six residents who scored nine patients to estimate inter- and intra-rater reliability in two sessions. Consultation with experts has established content validity of the instrument. Reliability studies demonstrated an intra-class correlation coefficient (ICC) for inter-rater reliability of 0.86 for the activity score (95% confidence interval (CI) = 0.73- 0.99)- and of 0.92 for the damage score (95% CI = 0.85- 1.00). The Spearman’ s ρ (Sp) for intra-rater reliability for the activity score was 0.96 (95% CI = 0.89 to 1.00) and for the damage score Sp was 0.99 (95% CI = 0.97- 1.00). Clinical responsiveness needs to be evaluated in a prospective clinical trial, which is ongoing.展开更多
目的:采用网络药理学和分子对接的研究方法,探究白芍治疗系统性红斑狼疮脑病(NPSLE)的有效成分及作用机制。方法:利用中药系统药理学数据库与分析平台(TCMSP)筛选白芍生物活性成分及潜在靶点;运用Genecards数据库收集NPSLE的疾病靶点;...目的:采用网络药理学和分子对接的研究方法,探究白芍治疗系统性红斑狼疮脑病(NPSLE)的有效成分及作用机制。方法:利用中药系统药理学数据库与分析平台(TCMSP)筛选白芍生物活性成分及潜在靶点;运用Genecards数据库收集NPSLE的疾病靶点;利用在线韦恩图绘制平台Venny2.1得到二者共同的靶点,将共同靶点导入STRING数据库构建蛋白质相互作用网络,并利用Cytoscape3.8.0进行可视化处理;通过Metascape在线软件对靶点进行基因本体(Gene Ontology,GO)分析、京都基因与基因组百科全书(Kyoto Encylopaedia of Genes and Genomes,KEGG)通路富集分析,探究相关的生物过程与信号通路;应用Cytoscape3.8.0构建“成分—靶点—通路”网络;最后通过AutoDock软件对药物的主要活性成分及核心作用靶点进行分子对接验证。结果:共获得白芍的13个化学成分、70个潜在作用靶点和740个NPSLE相关作用靶点,其中白芍与NPSLE共同作用靶点有31个;PPI网络显示处于核心地位的靶点为白细胞介素(IL)-6、肿瘤坏死因子(TNF)、CASP3等,KEGG通路富集分析筛选得到83条与白芍治疗NPSLE相关通路,主要作用于IL-17信号通路、TNF信号通路、流体剪切应力和动脉粥样硬化、细胞凋亡、雌激素信号通路等。分子对接结果显示,主要活性成分能够分别与代表性的靶点结合并展现出较好的亲和力。结论:白芍对通过“多成分—多靶点—多途径”的特点与优势作用于NPSLE,为中医药治疗NPSLE的临床应用奠定了基础。展开更多
文摘We developed and validated a measurement instrument (CLASI-Cutaneous Lupus Erythematosus Disease Area and Severity Index) for lupus erythematosus that could be used in clinical trials. The instrument has separate scores for damage and activity. A group of seven American Dermato-Rheumatologists and the “ American College of Rheumatology Response Criteria Committee on SLE (systemic lupus erythematosus)” assessed content validity. After a preliminary session, we conducted standardized interviews with the raters and made slight changes to the instrument. The final instrument was evaluated by five dermatologists and six residents who scored nine patients to estimate inter- and intra-rater reliability in two sessions. Consultation with experts has established content validity of the instrument. Reliability studies demonstrated an intra-class correlation coefficient (ICC) for inter-rater reliability of 0.86 for the activity score (95% confidence interval (CI) = 0.73- 0.99)- and of 0.92 for the damage score (95% CI = 0.85- 1.00). The Spearman’ s ρ (Sp) for intra-rater reliability for the activity score was 0.96 (95% CI = 0.89 to 1.00) and for the damage score Sp was 0.99 (95% CI = 0.97- 1.00). Clinical responsiveness needs to be evaluated in a prospective clinical trial, which is ongoing.
文摘目的:采用网络药理学和分子对接的研究方法,探究白芍治疗系统性红斑狼疮脑病(NPSLE)的有效成分及作用机制。方法:利用中药系统药理学数据库与分析平台(TCMSP)筛选白芍生物活性成分及潜在靶点;运用Genecards数据库收集NPSLE的疾病靶点;利用在线韦恩图绘制平台Venny2.1得到二者共同的靶点,将共同靶点导入STRING数据库构建蛋白质相互作用网络,并利用Cytoscape3.8.0进行可视化处理;通过Metascape在线软件对靶点进行基因本体(Gene Ontology,GO)分析、京都基因与基因组百科全书(Kyoto Encylopaedia of Genes and Genomes,KEGG)通路富集分析,探究相关的生物过程与信号通路;应用Cytoscape3.8.0构建“成分—靶点—通路”网络;最后通过AutoDock软件对药物的主要活性成分及核心作用靶点进行分子对接验证。结果:共获得白芍的13个化学成分、70个潜在作用靶点和740个NPSLE相关作用靶点,其中白芍与NPSLE共同作用靶点有31个;PPI网络显示处于核心地位的靶点为白细胞介素(IL)-6、肿瘤坏死因子(TNF)、CASP3等,KEGG通路富集分析筛选得到83条与白芍治疗NPSLE相关通路,主要作用于IL-17信号通路、TNF信号通路、流体剪切应力和动脉粥样硬化、细胞凋亡、雌激素信号通路等。分子对接结果显示,主要活性成分能够分别与代表性的靶点结合并展现出较好的亲和力。结论:白芍对通过“多成分—多靶点—多途径”的特点与优势作用于NPSLE,为中医药治疗NPSLE的临床应用奠定了基础。
